Search clinical trials for: PK and safety

Total 474604 results

Agios Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period (ACTIVATE-KidsT)

Pediatric Pyruvate Kinase Deficiency | Pediatric Hemolytic Anemia

United States, Spain, Denmark, Turkey, Netherlands, Czechia, United Kingdom, Germany, Canada, Switzerland
Processa Pharmaceuticals

Active, not recruiting

A Study of the Safety and PK of PCS6422 (Eniluracil) With Capecitabine in Patients With Advanced, Refractory GI Tract Tumors

Advanced Cancer | Refractory Cancer | Tumor Gastric

United States
Octapharma

Active, not recruiting

Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease VWD) Patients <6 Years of Age

Von Willebrand Disease

United States, Moldova, Republic of, Czechia, Germany, North Macedonia, Russian Federation, Ukraine
Anthos Therapeutics, Inc.
The TIMI Study Group; Fortrea

Active, not recruiting

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation (AZALEA-TIMI 71)

Stroke | Atrial Fibrillation (AF)

United States, Canada, Czechia, Hungary, Korea, Republic of, Poland, Taiwan
Vir Biotechnology, Inc.
GlaxoSmithKline

Completed

A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants

Covid19

United States
Novartis Pharmaceuticals

Terminated

Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

Immune Thrombocytopenia (ITP) | Cold Agglutinin Disease (CAD)

United States, Spain, Germany, Korea, Republic of, United Kingdom, Italy
Alexion Pharmaceuticals, Inc.
Celerion

Completed

Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants

Healthy

United Kingdom
Incyte Corporation

Active, not recruiting

A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND)

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States, Spain, France, Italy, Belgium, Germany, Austria
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Metastatic Hormone-Sensitive Prostate Cancer

Taiwan, Poland, United States, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Peru, Russian Federation, Spai... and more
Genmab
BioNTech SE

Active, not recruiting

GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies

Solid Tumor

Japan
Five Prime Therapeutics, Inc.

Completed

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Gastric Cancer | Advanced Solid Tumors | Transitional Cell Carcinoma of the Bladder

Korea, Republic of, United States, Taiwan
AJNA Australia Pty Ltd

Active, not recruiting

A SAD, MAD and Food Effect Study to Evaluate the Safety, Tolerability, PK, and PD of AJA001 in Healthy Subjects

Healthy Volunteers

Australia
Alebund Pharmaceuticals

Completed

A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in Healthy Chinese Participants

Healthy Subjects

China
Alebund Pty Ltd

Completed

A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects

Healthy Subjects

Australia
Optinose US Inc.

Completed

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps

Chronic Rhinosinusitis

United States, United Kingdom, Bulgaria, Canada, Georgia, Poland, Russian Federation, Sweden
Novartis Pharmaceuticals

Completed

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants

Hepatic Impairment

Hungary
Harpoon Therapeutics

Active, not recruiting

A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma of Bone

United States, France, Spain
Genentech, Inc.

Active, not recruiting

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Advanced/Metastatic Tumors

Spain, United States, Korea, Republic of, Australia, France, Japan, Canada
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.

Suspended

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
argenx

Completed

IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers

Healthy Volunteers
HighField Biopharmaceuticals Corporation

Completed

Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers

Healthy

United States
Sanofi

Completed

A Study of the Safety, Tolerability, and Bioavailability of Orally Administered Venglustat in Healthy Adult Participants

Healthy Volunteers

United States
Incyte Corporation

Active, not recruiting

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, China, Japan, France, Turkey, Germany, Israel, Poland, Belgium, Italy, Austria, Denmark, Finland, Norway
Amgen

Active, not recruiting

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

KRAS p.G12C Mutant Advanced Solid Tumors

United States, France, Canada, Spain, Belgium, Korea, Republic of, Austria, Australia, Hungary, Greece, Germany, Japan, Romania, Switzerland, Brazil, Portugal
Ono Pharmaceutical Co. Ltd

Suspended

Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685

Plaque Psoriasis

United Kingdom, Moldova, Republic of, Romania
Incyte Corporation

Active, not recruiting

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, Belgium, France, Israel, China, Japan, Italy, Germany, Taiwan, Poland, Austria, Finland, Hungary, Norway, Romania, Turkey
University of Arkansas

Withdrawn

PK and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia

Acute Kidney Injury | Hypoxic-Ischemic Encephalopathy | Caffeine

United States
IrsiCaixa
Hospital Clinic of Barcelona; University of Oxford; Germans Trias i Pujol Hospital and other collaborators

Completed

Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals

HIV

Spain
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

Breast Neoplasms

China
Ono Pharmaceutical Co. Ltd

Completed

Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and PK of ONO-2910 in Japanese and Caucasian Subjects

Healthy Volunteers

Japan
Ono Pharmaceutical Co. Ltd

Completed

Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male Subjects

Healthy Volunteers

Japan
SFJ Pharmaceuticals, Inc.

Completed

Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects

Healthy

United States
Telix Pharmaceuticals (Innovations) Pty Limited

Completed

64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study) (CUPID)

Metastatic Prostate Cancer

Australia
BenevolentAI Bio

Completed

Study Investigating the Safety, Tolerability, PK and Food Effect of BEN8744.

Healthy Volunteer Study

United Kingdom
UCB Biopharma SRL

Completed

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharamacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

Healthy Study Participants

United States
Seres Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

Allogeneic Hematopoietic Stem Cell Transplantation

United States
Changzhou Qianhong Bio-pharma Co., Ltd.

Completed

Study to Assess PK, Safety and Tolerability Early in Healthy Subjects

Acute Ischemic Stroke

China
Luye Pharma Group Ltd.

Active, not recruiting

Comparative Efficacy, Safety, PK, and Immunogenicity Study

Osteoporosis, Postmenopausal

Poland, United States, Czechia, Bulgaria, Japan
Changzhou Qianhong Bio-pharma Co., Ltd.

Completed

Study to Assess PK, Safety and Tolerability in Healthy Subjects

Acute Ischemic Stroke

China
Genentech, Inc.
BioNTech SE

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma. (IMCODE001)

Advanced Melanoma

United States, Spain, Belgium, Australia, Germany, United Kingdom
Peptomyc S.L.

Terminated

Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (MYCure)

Pancreatic Cancer | Advanced Solid Tumors | CRC

Spain
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin UK, Ltd.

Completed

A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma

Multiple Myeloma | Chronic Lymphocytic Leukaemia | B-cell Non-Hodgkin's Lymphoma

United Kingdom
Luye Pharma Group Ltd.

Enrolling by invitation

Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Visterra, Inc.

Terminated

A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and With Autoimmune Disease)

Autoimmune Diseases

New Zealand, Germany, Bulgaria, Moldova, Republic of, Netherlands
Pfizer

Completed

A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

Arthritis Juvenile Idiopathic

United States, Belgium, Spain, Canada, Mexico, Turkey, Israel, China, Slovakia, Hungary, India, Argentina, Brazil, Germany, South Africa, Poland, Ukraine, Italy, Costa Rica, Russian Federation, United Kingdom
Shanghai Henlius Biotech

Active, not recruiting

A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects

Multiple Myeloma

China
Shanghai Henlius Biotech

Active, not recruiting

A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma

Solid Tumor and Lymphoma

China
Spero Therapeutics
United States Department of Defense

Completed

Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function

Renal Impairment

New Zealand
TJ Biopharma Co., Ltd.

Terminated

A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)

China
Forma Therapeutics, Inc.
Medpace, Inc.

Completed

A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients

Healthy Volunteers | Sickle Cell Disease

United States

3

Subscribe